B7-H3 CAR T Cell Therapy for Pediatric Brain Tumors

This study focuses on testing a new type of treatment for children and young adults with specific types of brain tumors, known as diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), and certain recurrent or difficult-to-treat central nervous system tumors. The treatment involves using a patient's own T cells, a type of immune cell, which are specially modified to attack cancer cells that have a specific marker called B7H3. This study aims to see if enough of these modified T cells can be made and safely given to patients directly into the brain through a special tube. This approach is important because it might offer a new way to target and treat these challenging brain tumors directly at the site. Participants in the study will undergo a process where their T cells are collected and then engineered in a lab to recognize and attack the tumor cells. The treatment is given in two courses, with the T cells being delivered into the brain either into the space where the tumor was removed or through the ventricular system, depending on the type and location of the tumor. There are three different treatment plans based on these factors. The study will closely monitor the safety of this treatment by tracking any side effects and measuring how the T cells move and interact with the body. MRI scans and other tests will be used to evaluate the treatment's effect on the tumor, and patients might continue receiving the treatment if it is well-tolerated and beneficial.